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Abstract
Purpose—To investigate factors associated with female young adult cancer survivors’ (YCS) use 
of fertility care (FC), including consultation or fertility treatment, after completing their cancer 
treatment.
Methods—In this cross-sectional study, females between that ages of 18 and 35 years who had 
been diagnosed with childhood, adolescent, or young adult cancers completed a 20-min web-based 
survey that included demographics, reproductive history, use of FC, fertility-related informational 
needs, and reproductive concerns.
Results—A total of 204 participants completed the survey. Participants’ mean age was 28.3±4.5 
years. Thirty (15%) participants reported using FC after cancer treatment. The majority of 
participants recalled not receiving enough information about FP options at the time of cancer 
diagnosis (73%). In multivariable analysis, those with higher concerns about having children 
because of perceived risk to their personal health (P=0.003) were less likely to report use of FC 
after cancer treatment. Those who had used FC before cancer treatment (P=0.003) and who felt 
less fertile than age-matched women (P=0.02) were more likely to use FC after their cancer 
treatment.
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Conclusions—While most YCS in this cohort believed that they did not receive enough 
information about fertility and most wanted to have children, the vast majority did not seek FC. 
The findings of this study offer further evidence of the need for improved education and emotional 
support regarding reproductive options after cancer treatment is completed. Targeted discussions 
with YCS about appropriate post-treatment FC options may improve providers’ capacity to help 
YCS meet their parenthood goals.
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Introduction
Infertility is one of the most common long-term problems reported by female young cancer 
survivors (YCS) [1]. Cancer treatments such as radiation and chemotherapy have significant 
potential to cause damage to ovarian germ cells, which would lead to a range of future 
scenarios, including sterility, early menopause, diminished fertility, or no problems at all [2–
4]. YCS are less likely to report pregnancy than their siblings or population control subjects 
[5–7]. There are also studies reporting a higher rate of premature ovarian failure in YCS 
compared to their female siblings [4, 8]. Infertility can have a significant impact on a 
woman’s life after cancer, affecting her personal relationships, future family planning, and 
concerns about pregnancy and birth [9, 10]. Considering the high survival rate in cancer 
patients [11], reproductive concerns resulting from cancer treatment are an important quality 
of life (QOL) issue among YCS [12].
Due to the heightened awareness of QOL after cancer including reproductive health, the 
topic of fertility care (FC) has evolved in clinical importance and, in turn, there is a higher 
demand from the patients themselves [13]. While most current FC efforts focus on 
preserving fertility prior to cancer treatment, FC after cancer treatment is also important in 
terms of monitoring reproductive health and exploring FC and other options to assist patients 
who are ready to start a family. With the low uptake rate of fertility preservation treatment 
prior to cancer treatment [14], it may be even more important to offer FC, including fertility 
treatment where appropriate, after cancer treatment to patients who missed the opportunity 
prior to their cancer treatment. While it is recommended for survivors of childhood, 
adolescent, and young adult cancer to be referred to a fertility specialist to discuss and 
monitor their reproductive health after cancer treatment [15], there is a paucity of data about 
the frequency of their pursuing FC after cancer treatment.
We aim to describe YCS’ use of FC after completing cancer treatment and the factors related 
to use of post-treatment FC. To evaluate our question, we analyzed web-based survey data 
from a diverse group of female YCS.
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Patients and Methods
Participants and procedures
Between March and September 2012, we enrolled female young adult-aged cancer survivors 
to complete a 20-min web-based survey. The primary goal of the cross-sectional study was 
to determine the reproductive health outcomes and concerns of YCS. The study recruited 
female YCSs between the ages of 18 and 35 years who had childhood, adolescent, or young 
adult cancers. This age range represents women in their reproductive years when fertility 
and pregnancy rates are highest in the general U.S. population [16]. All participants were at 
least one year post-diagnosis, not currently pregnant, and English-speaking. Eligibility 
criteria did not include current cancer treatment status. Most participants were recruited via 
online social media outlets and local community outreach efforts [17]. Potential participants 
completed a web-based screening form and, if eligible, were provided electronic informed 
consent and then linked to the web-based survey. Eighty six percent of those eligible 
completed the survey. The University of California, San Diego Institutional Review Board 
approved the study.
Data collection and measurement
The web-based survey collected self-reported information about demographics, cancer 
characteristics including diagnoses and type of treatment received, and reproductive history 
including pregnancy attempts, births, miscarriages, and infertility. We assessed reproductive 
history and pregnancy plans using standard questions from the National Survey for Family 
Growth (e.g., pregnancy and birth outcomes; desire for children) [18]. We used the Time to 
Pregnancy measure to evaluate time between initiating an attempt to conceive and 
conception, with more than 12 months indicating infertility [19], and the Penn Ovarian 
Aging Study Menstrual Questionnaire to evaluate menstrual pattern data over the past year 
[20].
Patient-provider communication about fertility at the time of cancer diagnosis was assessed 
by a series of questions, such as, “Before your cancer treatment began, did a doctor, nurse, 
or other medical professional talk with you and/or your family about the possible impact of 
cancer treatment on your future fertility (ability to become pregnant)?” We further 
characterized participants’ fertility-related information needs at the time of cancer diagnosis 
using the following three items, “Thinking back to the time of your cancer diagnosis and 
information that you or your family may have wanted or needed about fertility or fertility 
preservation options, please say whether you strongly disagree, disagree, neither agree nor 
disagree, agree, or strongly agree with each statement. I and/or my family 1) Needed 
information that we did not know how to get about fertility after cancer treatment and FP 
options; 2) Received enough information from a medical professional about how my future 
fertility could be impacted by my cancer treatment; and 3) Were too overwhelmed at the 
time of my cancer diagnosis to consider how my fertility could be impacted by my cancer 
treatment.” These survey items were pilot tested, and refined during a series of focus groups 
and cognitive interviews with young female cancer survivors [21]. This process focused on 
ensuring that items were understood as intended.
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The 18-item Reproductive Concerns After Cancer (RCAC) scale measures feelings about 
having biological children now or in the future [22]. It includes the following six subscales, 
each of which has been shown to have high internal consistency (as reflected by Cronbach’s 
α): Fertility potential (α = 0.86) (e.g., “I am afraid I won’t be able to have any (more) 
children”); Partner disclosure of fertility status (α = 0.88) (e.g., “I worry about telling my 
(potential) spouse/partner that I may be unable to have children”); Child’s health (α = 0.88) 
(e.g.,” I am worried about passing on a genetic risk for cancer to my children”); Personal 
health (α = 0.83) (e.g., “I am scared of not being around to take care of my children 
someday”); Acceptance of possibly not having children (α = 0.82) (e.g., “I can accept it if 
I’m unable to have (more) children”); and Becoming pregnant (α = 0.78) (e.g., “I worry that 
getting pregnant (again) would take too much time and effort”).The response scale uses a 
five-point Likert scale ranging from 1=“Strongly disagree” to 5=“Strongly agree” [22].
Participants also reported on their perceived fertility compared to other women their age, 
importance of having biological children, whether cost had ever prevented them from using 
FC, and use of FC before and after their cancer treatment.
The primary outcome was defined as the use of FC (fertility treatment and/or consultation 
with a fertility specialist) after completing cancer treatment. Fertility treatment was defined 
by exposure to fertility drugs (such as recombinant gonadotropins and oral ovulation 
induction drugs) and/or assisted reproductive techniques (ART, such as intrauterine 
insemination and in vitro fertilization).
Statistical analysis
Descriptive statistics were used to characterize the study cohort, and were calculated as 
frequency and percentage for categorical data and mean and standard deviation (SD) for 
continuous data. To avoid assumptions of linearity, continuous variables were dichotomized 
for subsequent statistical analysis based of the clinical implication (e.g.: having fewer than 
10 periods in 12 months is defined as abnormal menstrual period pattern) and statistical 
representativeness (e.g.: median value). Summary RCAC scores were calculated for each 
subscale and for the scale as a whole, with higher scores indicating more concern [23]. 
Associations of use of FC with demographics, reproductive and cancer history and 
perception about future parenthood and own fertility were evaluated by first categorizing 
continuous variables and then using chi-square tests or Fisher’s Exact test. With the 
exception of cancer type, categorizations were all dichotomous in order to avoid issues with 
small cell sizes. Age, which was considered to be clinically related to the use of FC, and 
variables that were statistically significant (p < 0.05) determinants of the use of FC in the 
bivariate analysis were considered for inclusion in the multivariable model. The final model 
was specified using backward selection from this list as initial covariates. Those with a p-
value of less than 0.10 were retained in the final model. Statistical analyses were conducted 
using SAS version 9.3 (Cary, NC).
Results
A total of 204 participants completed the survey. Their mean ages at cancer diagnosis and 
study participation were 22.9±7.6 years and 28.3±4.5 years, respectively. At participation, 
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6% were age 20 or younger, 24% were 21–25, 33% were 26–30, and 38% were 31–35 years 
old. Mean time since cancer diagnosis was 5.7±5.4years.The majority of subjects (72%) had 
an education level of college graduation or more (Table 1). Eighty percent of the participants 
were white and 49% were currently in a relationship. Most subjects were nulliparous at the 
time of cancer diagnosis (87%) and study participation (83%). Fifty-nine women (29%) had 
ever tried to conceive, and, of those, 15 (25%) reported a history of infertility (unable to get 
pregnant after more than one year of trying) before cancer diagnosis.
Hematologic cancer (37%) was the most common cancer diagnosis followed by breast 
(17%) and gynecologic (7%) cancers. Three fourths of participants (75%) received 
chemotherapy for cancer treatment and 38% of those reported received alkylating 
chemotherapeutic agents.
Forty-one participants (20%) had had a consultation with a fertility specialist between their 
cancer diagnosis and the commencement of cancer treatment, and among those, 19 (46%) 
had pursued ART. Eight patients (20%) had used gonadotropin-releasing hormone agonist to 
suppress their ovaries. About a quarter of participants (n=55, 27%) reported receiving 
enough information from a medical professional about FP options at the time of their cancer 
diagnosis. Most (n=131, 64%) reported that they were too overwhelmed at the time of their 
cancer diagnosis to consider FP options (strongly agree or agree that they were too 
overwhelmed) (Table 2).
Use of fertility care after cancer treatment
Of 204 participants, 30 (15%) sought FC after cancer treatment. A consultation with a 
fertility specialist was the most common type of FC (28 out of 30 participants, 93%). Eight 
participants (4%) used fertility drugs or pursued ART.
In unadjusted analyses, history of infertility before cancer diagnosis was significantly 
associated with the greater use of FC after cancer treatment (P=0.03). Women who had 
regular menstrual cycles (10 or more periods in the past 12 months) were less likely to use 
FC after cancer treatment (P=0.005). Demographics such as age, race, education, parity, 
partner status, duration of survivorship and the type of cancer and cancer treatments were 
not associated with the use of FC after cancer treatment (Table 1).
Participants who saw a fertility specialist before their cancer treatment were also more likely 
to pursue FC after their cancer treatment (P <0.0001). Those who felt too overwhelmed at 
the time of diagnosis to consider FP options were less likely to pursue FC after cancer 
treatment (P=0.01). However, receiving enough information about FP options at the time of 
cancer diagnosis was not associated with the use of FC after cancer treatment (P=0.97) 
(Table 2).
Participants who felt that they were less fertile than other women of their age were more 
likely to have used FC after cancer treatment compared to participants who felt that they 
were as fertile as or more fertile than women their age (P=0.005). While about three-quarters 
of participants reported that having biological offspring was important or very important in 
their lives, this characteristic was not related to use of FC after cancer treatment (P=0.40). 
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FC use after cancer treatment was not associated with overall degree of reproductive 
concerns as reflected by the RCAC score (P=0.59). However, women who did not pursue FC 
after cancer treatment had greater levels of reproductive concerns related to their personal 
health compared to women who did access FC (P=0.003) (Table 3).
In multivariable analysis, participants who had higher reproductive concerns related to their 
personal health (OR 0.81 [95% CI: 0.71, 0.93], P=0.003) were less likely to have pursued 
FC after cancer treatment. On the contrary, participants who had pursued fertility 
consultation prior to cancer treatment were more likely to use FC after cancer treatment (OR 
3.91 [95% CI: 1.61, 9.55], P=0.003). Those who felt less fertile than age-matched women 
also had higher odds of seeking FC after cancer treatment as compared to women who felt 
as fertile or more fertile than women their age (OR 4.60 [95% CI: 1.26,16.79], p=0.02). 
Estimates from multivariable models were not substantially different from unadjusted 
models (Table 4).
Discussion
Previous reports show that a threat to future fertility is a significant concern for female YCS 
[24–26], and that patients are receiving inadequate or conflicting information regarding FP 
[27], are uncertain about their fertility status, and feel regret about not having options [28, 
29]. Despite the heightened awareness of the importance of fertility and discussion of FP 
options with YCS, only a small proportion of patients receive FC either before or after their 
cancer treatment [14, 30–32]. There are several studies reporting characteristics of the 
participants who seek for FC prior to initiation of treatment [14, 27], this is the first to 
investigate the characteristics of the participants who seek for FC after the completion of 
treatment. In our study of YCS, where the average age was 28.3 years and average duration 
of survivorship was 5.7 years, only 15% of participants had accessed FC after cancer 
treatment and only 4% had used fertility drugs or pursued ART. This represents an important 
target audience for improved survivorship care because young women who have had 
gonadotoxic cancer treatment can face a shorter than expected window of fertility [28, 33, 
34]. It is important for those desiring biological children to seek medical advice as soon as 
possible after completing their treatment to preserve their parenthood options.
The acquisition of information is related to patients’ high-quality decision making [35]. 
Correspondingly, this study found that exposure to fertility information before cancer 
treatment is associated with higher uptake of FC after completing treatment. Patients who 
saw a fertility specialist before their cancer treatment also tended to have follow-up 
monitoring with a fertility specialist after cancer treatment. Only 30 women in this study 
initiated FC after their cancer treatment, and 13 (43%) of those had also reported FC prior to 
their cancer treatment. This suggests a need for improved knowledge of and access to post-
treatment FC options for young survivors who want to have children.
An individual’s perceived need for medical care is one of the major promoting factors of 
healthcare-seeking behavior [36]. In the multivariable model, those who reported feeling less 
fertile than age –matched women had significantly higher odds of using FC after their cancer 
treatment. This is in line with the trend for lower odds of post-treatment FC that we 
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observed among women having normal periods in the past year, although this variable did 
not emerge as a significant predictor in the multivariable model. Those who feel more fertile 
or are reassured of their fertility by regular menstrual periods may be at a disadvantage when 
making decisions about FC after cancer treatment because post-treatment menstrual pattern 
is not a reliable marker of fertility [5]. Unexpectedly, we found no difference in use of FC 
after cancer between women who said that biological offspring were important to them 
compared to those who did not. This could be explained by lack of knowledge about the 
medical options available and advantage of FC after cancer treatment. Improved counseling 
and education focused on the options available to monitor and preserve fertility after cancer 
treatment may be of benefit to those YCS who want to have biological children.
A decision to pursue parenthood is complex, and there are even more factors to consider for 
cancer survivors and women with chronic health conditions [22]. In our study, YCS who 
were more concerned about their personal health (i.e., the potential impact of a recurrence or 
survival on their children) had lower odds of accessing FC after their cancer treatment. 
Qualified emotional support in survivorship, such as by a clinical psychologist or social 
worker, can provide an important and needed opportunity for YCS to discuss such concerns 
and may also improve communication between YCS and their other healthcare providers 
[37]. This also underscores the importance of a multidisciplinary approach to managing the 
overall health of cancer survivors. A better understanding of how women cope with their 
personal health concerns in relation to their decisions about parenthood could assist in the 
development of improved processes and communication tools to support the overall health 
of YCS.
Despite the growing focus on the importance of fertility for YCS, this is the first study to 
evaluate factors associated with female YCS’ use of FC after completing their cancer 
treatment. While it remains a priority to discuss FP options at the time of cancer diagnosis, 
many feel unprepared to fully consider their options at that time. Improved access to FC 
after cancer treatment provides an important opportunity for education and support, and 
could lead to more available options for biological parenthood, such as through ovarian 
reserve monitoring and earlier or more aggressive fertility treatments. This study also 
provide insight on key factors that are related to the patients’ uptake of FC after their cancer 
treatment, which could help in the development of an improved patient care system to 
provide appropriate post-treatment FC and FP options to those who are considering future 
parenthood.
Our study has several limitations. First, the cross-sectional design limits our ability to make 
causal inferences. For example, it is possible that women who reported higher odds of 
seeking FC after their cancer treatment felt less fertile because of information that had been 
provided to them during a fertility consultation, rather than seeking care because they felt 
less fertile. We did not directly assess reasons for accessing FC before and after cancer 
treatment or YCS’ perceptions about infertility risk based on treatment regimen. It is 
interesting that only a fraction of participants (25%) reported that they had FC before their 
cancer treatment, but our study cannot determine if this is due to recall bias, barriers such as 
limited access, personal preferences, or other reasons. Longitudinal studies are needed to 
provide insight regarding when and why YCS access, or fail to access, fertility-related 
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services. The sample size and the heterogeneity of our sample also limit our ability to adjust 
for all potential confounders, including cancer type and treatment. It is possible that some 
women did not recall use of fertility-related services before or after cancer; we did not 
collect medical record data, so we do not have formal documentation of these visits. Because 
many participants were recruited from social media and chose to participate in a fertility-
focused research study, they may be more interested in this topic then the general YCS 
population, which may limit generalizability.
In conclusion, while most YCS in this cohort reported wanting to have children and believed 
that their fertility may have been compromised, only a small proportion reported using FC 
after completing their cancer treatment. Post-treatment FC represents an important 
opportunity for intervention and education earlier in survivorship that could keep the option 
of biological parenthood open for young survivors who are considering future parenthood. 
Comprehensive survivorship care to monitor reproductive health, assess parenthood 
intentions, address reproductive concerns, and provide emotional support could facilitate 
decision-making and appropriate referral for consultation about fertility. Studies that further 
explore unmet needs and barriers related to FC after cancer could assist in the development 
of targeted approaches and communication tools to support the overall health of YCS who 
are considering biological children.
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Table 1
Demographic and medical determinants of use of fertility care services after cancer treatments (N=204).
Use of fertility care after cancer
treatment
Yes
(n=30)
n (%)
No
(n=174)
n (%)
P-value
Demographics
Age (yrs) 29.4±5.1 28.1±4.4 0.16
≤30 15 (12) 112 (88) 0.13
>30 15 (19) 62 (81)
Education 0.38
Did not complete college 6 (11) 51 (89)
Completed college 24 (16) 123 (84)
Race 0.33
Caucasian 22 (14) 141 (87)
Non-Caucasian 8 (20) 33 (80)
Relationship status 0.84
Married or committed relationship 19 (16) 103 (84)
Not in a relationship 11 (14) 71 (87)
Employed 0.79
Yes 25 (15) 147 (85)
No 5 (16) 27 (84)
Current healthcare insurance 0.99
Yes 29 (15) 165 (85)
No 1 (10) 9 (90)
Reproductive History
Nulliparous at study participation 0.61
Yes 24 (14) 145 (86)
No 6 (17) 29 (83)
Nulliparous at cancer diagnosis 0.38
Yes 28 (16) 149 (84)
No 2 (7) 25 (93)
Number of periods in the past 12 months 0.005
≥ 10 11 (37) 19 (63)
9 or less 111 (64) 63 (36)
Infertility at time of cancer diagnosisa 0.03
Yes 7 (47) 8 (53)
No 7 (16) 37 (84)
Cancer characteristics and treatment
Cancer type 0.64
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Use of fertility care after cancer
treatment
Yes
(n=30)
n (%)
No
(n=174)
n (%)
P-value
Hematologic 8 (11) 66 (89)
Breast 6 (17) 29 (83)
Gynecologic 3 (10) 27 (90)
Thyroid 5 (24) 16 (76)
Soft tissue 1 (8) 11 (92)
Brain 1 (8) 11 (92)
Otherb 6 (30) 14 (70)
Life stage at cancer diagnosis 0.55
Childhood (≤ 14 yrs) 5 (19) 21 (81)
Adolescence (15 – 20 yrs) 3 (13) 21 (88)
Young adulthood (20 – 35 yrs) 22 (14) 132 (86)
Cancer stage or risk group 0.99
Advanced stagec 10 (15) 57 (85)
Early staged 20 (15) 117 (85)
Higher risk cancer treatment
Alkylating chemotherapy 13 (18) 59 (82) 0.41
Bone marrow or stem cell transplant 4 (25) 12 (75) 0.26
Duration of survivorship (yrs) 0.07
1 – 4 15 (11) 117 (89)
5 or more 15 (21) 57 (79)
Cancer recurrence 0.29
Yes 7 (21) 27 (79)
No 23 (14) 147 (86)
a
Include 59 women who had ever tried to get pregnant
b
Includes bone (6), genitourinary (2), lung (2), gastrointestinal (9) and thorax-pharynx (1) cancers
cStage 3 or more
dStage 2 or less
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Table 2
Association between accessibility to fertility care services and financial barriers at cancer diagnosis, and the 
use of fertility care services after cancer treatments (N=204).
Use of fertility care after cancer treatment
Yes
(n=30)
n (%)
No
(n=174)
n (%)
P-value
Had fertility care before cancer
treatment <0.0001
Yes 13 (32) 28 (68)
No 17 (10) 146 (90)
Needed information that we did not
know how to get about fertility after
cancer treatment and FP options
0.09
Yes 17 (20) 70 (80)
No 13 (11) 104 (89)
Received enough information from a
medical professional about fertility
after cancer treatment and FP
options
0.67
Yes 11 (13) 71 (87)
No 19 (16) 103 (84)
Were too overwhelmed at the time of
diagnosis to consider my fertility
after cancer treatment and FP
options
0.01
Yes 13 (10) 118 (90)
No 17 (23) 56 (77)
After cancer diagnosis, the cost has
ever prevented you from using any
FCa
0.89
Yes 9 (20) 35 (80)
No 18 (21) 66 (79)
aSeventy-six women were not applicable for this question
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Table 3
Association between perception about own fertility and future offspring and Reproductive Concerns After 
Cancer (RCAC) scale, and the use of fertility care services after cancer treatments (N=204).
Use of fertility care after cancer treatment
Yes
(n=30)
n (%)
No
(n=174)
n (%)
P-valued
Feeling about own fertility 0.005
Fertile 3 (5) 59 (95)
Less fertile 27 (20) 110 (80)
Important to have biologic offspringa 0.40
Yes 24 (17) 121 (83)
No 6 (11) 48 (89)
RCAC summary scoreb (Mean±SD) 57.5±11.7 58.7±10.9 0.59
RCAC subscale scoresc (Mean±SD)
Fertility potential 11.5±3.6 10.6±3.2 0.07
Partner disclosure 8.9±4.1 9.6±3.6 0.33
Child’s health 10.0±3.6 11.2±3.4 0.12
Personal health 8.3±2.5 10.3±3.4 0.003
Acceptance 9.1±3.2 7.9±2.8 0.06
Becoming pregnant 9.7±2.3 9.2±2.9 0.33
a
Five women did not complete this question
bOverall RCAC summary score, range 18–86
c
RCAC Subscale summary scores, range 3–15
d
Fisher’s exact test
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Table 4
Multivariable analysis for determinants of use of fertility care services after cancer treatment in female YCS 
(N=204)
Variables
Unadjusted odds
ratio
(95% CI)
P-value
Multivariable
adjusted odds ratio*
(95% CI)
P-value
Current age (years) 1.07(0.97, 1.20) 0.16
1.06
(0.97, 1.17) 0.20
Had fertility care
before cancer
treatment
3.99
(1.74, 9.12) 0.001
3.91
(1.61, 9.55) 0.003
Feel less fertile than
age-matched women
4.74
(1.38, 16.26) 0.01
4.60
(1.26, 16.79) 0.02
Higher reproductive
concerns about
personal healtha
0.84
(0.74, 0.95) 0.005
0.81
(0.71, 0.93) 0.003
*
Multivariable adjusted model includes all variables in the table.
a
RCAC, Personal health subscale score (range 3–15)
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